Related by context. All words. (Click for frequent words.) 86 placebo controlled 84 randomized double 83 randomized controlled 80 blind randomized 80 blind randomized placebo 80 double blind placebo 79 multicenter 79 randomized clinical 78 Phase III randomized 78 placebo controlled randomized 78 prospective randomized 77 multicenter randomized double 77 randomized 77 randomized multicenter 77 multicenter randomized 74 multicentre 74 placebo controlled Phase 74 multicentre randomized double 74 blind placebo controlled 74 prospective randomized controlled 74 multicenter randomized placebo controlled 74 randomized controlled trial 72 masked placebo controlled 72 double blinded randomized 72 randomized Phase III 72 blinded placebo controlled 71 placebo controlled clinical 71 controlled multicenter 71 blind randomized controlled 70 dose escalation trial 70 blind multicenter 70 multicenter placebo controlled 69 randomized controlled clinical 69 dose escalation study 69 multicentre randomized 68 Phase 1b clinical 68 multicenter Phase II 68 multicenter randomized controlled 68 Phase 2b study 68 prospective randomized placebo 68 prospective observational 67 single ascending dose 67 blind placebo 67 double blinded placebo 67 multicenter prospective 67 multicenter study 67 Phase 2a clinical 66 randomized multicentre 66 multicenter clinical 66 Phase III clinical 66 placebo controlled Phase III 66 Phase IIb trial 66 active comparator 66 label dose escalation 66 placebo controlled studies 66 prospective multicenter 66 label multicenter 66 randomized clinical trials 66 randomized Phase 66 phase IIa 66 Phase 2a trial 66 dose dose escalation 65 placebo controlled trials 65 TMC# C# 65 clinical trial 65 Phase IIb 65 Phase 2b clinical 65 blinded randomized 65 phase IIb clinical 65 multiple ascending dose 65 Phase III placebo controlled 65 randomized controlled clinical trials 65 Phase IIIb 65 ascending dose 65 multicenter Phase III 65 Phase 2b trial 65 randomized multicenter trial 64 dose escalation clinical 64 randomized controlled trials 64 pivotal Phase III 64 Phase 1b trial 64 Phase Ib clinical 64 NO# [002] 64 dose escalation Phase 64 prospective randomized multicenter 64 prospective multicenter randomized 64 prospective cohort 64 multicenter phase 63 HCV SPRINT 63 blinded randomized placebo controlled 63 phase IIb 63 Phase Ib 63 randomized blinded 63 nonrandomized 63 pivotal Phase 63 randomized #:# 63 multicenter multinational 63 phase Ib 63 Phase IIb clinical 63 Phase 2b randomized 63 Phase IIa trial 63 Phase 2b 63 Randomized 63 ADVANCE PD 63 multicenter Phase 63 RE LY ® 63 phase IIa clinical 63 Sorafenib HCC Assessment 63 Phase 1b 62 randomized trials 62 safety tolerability pharmacokinetics 62 trials RCTs 62 prospectively randomized 62 Phase IIa 62 dose escalation 62 mg dose 62 landmark ATHENA 62 Phase Ia 62 blind multicentre 62 placebo controlled dose escalation 62 LUX Lung 62 randomized Phase IIb 62 Placebo controlled 62 BRIM2 61 Phase IIa clinical 61 TG MV 61 VICTOR E1 61 safety tolerability 61 phase 2a 61 controlled dose escalation 61 Phase III 61 PRECiSE 61 randomized crossover 61 symptomatic BPH 61 BRIM3 61 pharmacokinetics PK 61 observational study 61 AIR CF1 61 multicentre study 61 Phase 1a 61 randomized controlled Phase 61 placebo controlled clinical trials 61 Randomised 61 tolerability 61 Phase 2a 61 subanalysis 61 dose cohorts 60 viral kinetic 60 multicenter randomized clinical 60 randomized blinded placebo 60 prospective nonrandomized 60 ascending doses 60 phase IIIb 60 AIR CF2 60 ROCKET AF 60 TAXUS ATLAS 60 ONTARGET 60 mg BID 60 PRE SURGE 60 Phase IIIb clinical 60 Phase Ib II 60 Multicenter 60 label multicenter Phase 60 dose regimens 60 RE LY 59 pharmacodynamics 59 Phase IIIb study 59 nab paclitaxel 59 desvenlafaxine succinate 59 substudy 59 Phase #/#a 59 blind randomized multicenter 59 label multicenter randomized 59 CLL8 59 dyskinesia PD LID 59 Phase III pivotal 59 observer blinded randomized 59 phase IIb study 59 AIR CF3 59 pharmacokinetic 58 EURIDIS 58 Initiated Phase 58 meta analysis 58 Traficet EN 58 SPIRIT III 58 non inferiority 58 Clinical Antipsychotic Trials 58 phase IIb trial 58 APEX PD 58 controlled multicenter Phase 58 Randomized Phase 58 teriflunomide 58 phase Ib clinical 58 Carotid Revascularization Endarterectomy vs. 58 Phase III randomized controlled 58 prospectively defined 58 mg QD 58 ExTRACT TIMI 58 ritonavir boosted 58 confirmatory Phase III 58 label dose titration 58 HPTN 58 TRANSFORMS 58 Phase 1a clinical 58 CALGB 58 ongoing Phase 1b 58 EDEMA3 58 #mg/day [001] 58 oral rivaroxaban 58 ECASS 58 treatment naive genotype 58 CAMMS# 58 safety tolerability pharmacokinetic 58 SCH # 58 investigational oral 58 retrospective cohort study 58 LEXIVA r 58 unblinded 58 HCV RESPOND 2 57 dosing cohorts 57 Randomized controlled 57 RG# ITMN 57 comparing XIENCE V 57 randomized controlled multicenter 57 evaluating tivozanib 57 analgesic efficacy 57 subgroup analyzes 57 mg administered orally 57 ENESTnd 57 placebo 57 DAPT 57 Parkinson disease levodopa induced 57 GAMMAGARD 57 adalimumab 57 Betaferon ® 57 monotherapy 57 prospective multicentre 57 ToGA 57 Prostate Lung Colorectal 57 treatment naïve genotype 57 dose titration 57 vicriviroc 57 RoACTEMRA 57 AIR2 Trial 57 randomized placebo 57 Phase IIb randomized 57 BOLDER II 57 Phase IIB 57 sorafenib Nexavar 57 pharmacokinetic PK study 57 oral deforolimus 57 AVOREN 57 ascending dose study 57 RRMS patients 57 confirmatory clinical 57 recurrent malignant glioma 57 administered subcutaneously 57 Phase III clinical trials 57 RG# [001] 57 #mg QD [002] 56 post hoc 56 Phase III trials 56 GOUT 56 BCIRG 56 pharmacokinetics 56 EchoCRT 56 GetGoal Phase III 56 Randomized Evaluation 56 lacosamide 56 Multicentre 56 RSD# oral 56 dose placebo controlled 56 pivotal bioequivalence 56 dose regimen 56 prospective observational cohort 56 Phase Ib clinical trials 56 multicentre randomized controlled 56 REALITY Trial 56 sunitinib malate 56 observational studies 56 fosbretabulin 56 riociguat 56 EVEREST II 56 randomized #:#:# 56 mg RDEA# 56 multinational multicenter randomized 56 NOXAFIL Oral Suspension 56 peginterferon alfa 2b 56 lixisenatide 56 relapsing remitting multiple sclerosis 56 multicenter trials 56 dosing regimens 56 CATIE AD 56 PREZISTA r 56 adjunctive placebo 56 APTIVUS 56 COMFORT II 56 Intervention Effectiveness 56 noninferiority 56 blinded placebo 56 glatiramer acetate 56 MEND CABG 56 IFN alfa 56 primary endpoint 56 longitudinal cohort study 56 recurrent glioblastoma multiforme 56 placebo controlled multicenter 56 candesartan cilexetil 56 dose escalation phase 56 NSABP B 56 risperidone Risperdal 56 CIMZIA TM certolizumab pegol 56 rosuvastatin 56 TRITON TIMI 56 factorial design 56 pharmacokinetic PK 56 ACTEMRA 56 primary hypercholesterolemia 56 ancrod 56 Phase #b/#a 56 relapsing multiple sclerosis 56 evaluating REVLIMID 56 pegylated interferon alfa 2a 56 Amrubicin 56 NCCTG 56 null responder HCV 56 posaconazole 56 Randomized Double Blind Placebo 56 mg doses 56 Communities ARIC study 56 brivaracetam 55 darunavir ritonavir 55 viral kinetics 55 mcg kg 55 efficacy 55 ACTEMRA TM 55 relapsed MM 55 blinded randomized controlled 55 CTA# Injection 55 CHAMPION PCI 55 Phase III VISTA 55 registrational Phase 55 Multiple Ascending Dose 55 Edge STudy 55 eculizumab 55 ORMD 55 dabigatran etexilate 55 dosing cohort 55 pegylated interferon alfa 2b 55 colesevelam HCl 55 pegylated liposomal doxorubicin 55 Phase IIb III 55 ADAGIO study 55 clinical pharmacology studies 55 HOPE TOO 55 bendamustine 55 multicentre prospective 55 phase III ACCLAIM 55 PFO migraine 55 efavirenz EFV 55 ANCHOR trial 55 metastatic HRPC 55 NLX P# 55 subcutaneously administered 55 Tolvaptan 55 Enzastaurin 55 pharmacodynamic profile 55 AEGR 55 beta2 agonist 55 Phase III confirmatory 55 RE SURGE 55 FAME Study 55 Pivotal Trial 55 ASTEROID 55 Phase Ib study 55 ACTIVE W 55 Efficacy 55 Phase II 55 PD LID 55 dose cohort 55 pharmacokinetic studies 55 CLARITY study 55 relapsing remitting MS 55 prucalopride 55 plus ribavirin 55 LITHE 55 INSPIRE Trial Phase III 55 AZILECT R 55 inhibitor RG# 55 BARI 2D 55 ABCSG 55 SPIRIT FIRST 55 #:# randomization 55 evaluable patients 55 goserelin 55 ENDEAVOR IV 55 pharmacodynamics PD 55 DU #b 55 Myocardial Infarction Study 55 perampanel 55 icatibant 55 PreCISe 55 metreleptin 55 Phase III multicenter 55 APTIVUS r 55 Placebo Controlled 55 evaluating Vectibix 55 Phase 2b kidney transplant 55 tolerability pharmacokinetics 55 MIST II 55 Randomized Clinical Trial 55 lubiprostone 55 venlafaxine XR 55 docetaxel chemotherapy 55 ABSORB trial 55 Phase III randomized placebo 55 Laquinimod 55 olanzapine Zyprexa 55 dosage regimens 55 fluticasone furoate 54 HCV infected 54 weekly subcutaneous injections 54 irbesartan 54 telaprevir dosing 54 Intervention Trial GAIT 54 ZYBRESTAT fosbretabulin 54 visilizumab 54 rALLy clinical trial 54 fostamatinib 54 thorough QT 54 NATRECOR ® 54 observational cohort study 54 MERLIN TIMI 54 randomized multicenter Phase III 54 EINSTEIN DVT 54 pharmacodynamic 54 diabetic neuropathic pain 54 ABSORB clinical 54 citalopram 54 randomized Phase 2b 54 nitazoxanide 54 Prospective Randomized 54 randomly assigned 54 Randomized Study 54 RIO Lipids 54 INCB# [001] 54 boosted protease inhibitor 54 safinamide 54 de novo kidney transplant 54 multicenter randomized Phase 54 neratinib 54 Ophena TM 54 CRx 54 SPIRIT IV 54 APPRAISE 54 OLYMPIA registry 54 EQUIP OB 54 clinical trials 54 CANCIDAS 54 eszopiclone 54 bosentan 54 low dose cytarabine 54 LIALDA 54 zonisamide SR 54 axitinib 54 secondary efficacy endpoints 54 CLARITY TIMI 54 Raloxifene Evaluation MORE 54 Cholesterol Levels SPARCL 54 mcg dose 54 basal bolus regimen 54 rotigotine 54 CIMZIA TM 54 Randomized Controlled 54 retrospective observational study 54 CA4P 54 RE LY trial 54 Phase III metastatic melanoma 54 secondary endpoint 54 registrational trial 54 daunorubicin 54 Neovascular AMD 54 FOLFOX 54 TAXUS IV 54 REVLIMID lenalidomide 54 Denufosol 54 carboplatin paclitaxel 54 antiviral activity 54 PRIMO CABG 54 primary endpoints 54 daily Infergen 54 retrospective cohort 54 bupropion SR 54 Phase #b/#a trial 54 pramlintide 54 n = 54 AVADO 54 e HEALING 54 Plicera 54 cetrorelix 54 pomalidomide 54 EORTC 54 ataluren 54 tocilizumab 54 ASCEND HF 54 Prostate Cancer Prevention 54 registrational 54 MIVI III 54 Microplasmin 54 dirucotide MBP# 54 insulin detemir 54 opioid induced bowel dysfunction 54 COPAXONE R 54 #mg BID [001] 54 ARIXTRA 54 unblinding 54 #mg dosing 54 PRoFESS 54 Multi Ethnic Study 54 MGd 54 satraplatin Phase 54 TMC# r 54 REYATAZ r 54 Randomized Placebo Controlled 54 II Clinical Trial 54 Randomized Phase II 54 mg/m2 dose 54 JAK inhibitor 54 EVIZON 54 primary efficacy endpoint 54 BR.# 54 sequential dose escalation 54 MabCampath 54 atorvastatin Lipitor 54 Randomized Double blind 54 Controlled Trial 54 sunitinib 53 Stenting Trial CREST 53 trastuzumab emtansine T DM1 53 canakinumab 53 SWOG 53 Intervention Effectiveness CATIE 53 Study ADX# 53 MIRCERA 53 HCV NS5B polymerase 53 Phase III psoriasis 53 multicenter dose escalation 53 docetaxel Taxotere R 53 stage IIIB 53 comparator arm 53 oral sapacitabine 53 AIM HIGH 53 phase IIb III 53 pharmacokinetic profile 53 Val HeFT 53 bolus injection 53 Pegasys ® 53 mcg BID 53 forodesine 53 rapid virologic response 53 refractory CLL 53 registrational clinical 53 ILLUMINATE 53 tolerated dose MTD 53 PEGINTRON TM 53 ABC/3TC 53 dexpramipexole 53 Dacogen injection 53 HGS ETR1 53 iniparib 53 RLAI 53 Phase III Clinical Trial 53 tacrolimus ointment 53 bevacizumab Avastin 53 tenofovir emtricitabine 53 mg TID 53 CIMZIA ™ 53 Sym# 53 PRECISE 53 hour bronchodilation 53 interferon gamma 1b 53 QD dosing 53 achieved statistical significance 53 dose pharmacokinetic 53 Adalimumab 53 tolerability profile 53 investigational protease inhibitor 53 aripiprazole Abilify 53 VIRAMUNE XR 53 ORACLE MS 53 lopinavir r 53 EMPHASIS HF 53 DSMB 53 rFVIIa 53 inhalations twice 53 rasagiline 53 alvespimycin 53 efficacy endpoints 53 paricalcitol 53 Phase Ib IIa 53 q8h 53 davunetide intranasal AL 53 NCT# ClinicalTrials.gov 53 CARE HF 53 cilostazol 53 pertuzumab 53 standard chemotherapy regimen 53 intravitreal injection 53 CombAT 53 peginterferon alfa 2a 53 PRTX 53 Betaferon R 53 DURATION 53 laquinimod 53 pramipexole 53 DASISION 53 relapsed myeloma 53 ZD# [001] 53 Aggressive Reduction 53 BoNTA 53 #mg dose [003] 53 Omacetaxine mepesuccinate 53 relapsed refractory multiple myeloma 53 #mg dose [001] 53 dacarbazine 53 Taxotere ® 53 pharmacokinetic parameters 53 tapentadol ER 53 mg kg dose 53 oral ridaforolimus 53 Safinamide 53 heFH 53 CYPHER ® Sirolimus eluting 53 JANUVIA 53 LPV r 53 AVERROES 53 TORISEL 53 VNP#M 53 Placebo Controlled Trial 53 SUCCEED trial 53 chlorambucil 53 demonstrated statistically significant 53 temsirolimus 53 IBS C 53 Val MARC 53 ORENCIA ® 53 superficial bladder cancer 53 Clinical Study 53 MSI #F 53 Pivotal Phase 53 EmbraceAC 53 retinal vein occlusion induced 53 bepotastine besilate nasal spray 53 NSABP 53 Pharmacokinetics PK 53 recurrent glioma 53 composite endpoint 53 fluvastatin 53 postmenopausal women 53 mcg albinterferon alfa 2b 53 STRIDE PD 53 pharmacodynamic effects 53 μg dose 53 rilonacept 53 chemoradiotherapy 53 pioglitazone 53 tasocitinib 53 tiotropium 53 Tocilizumab 53 CYPHER R Sirolimus eluting 53 Radiation Therapy Oncology 53 eltrombopag 53 atrasentan 53 ATACAND 53 INCB# [003] 53 Phase IIa trials 53 pimecrolimus cream 53 serotonin norepinephrine reuptake inhibitor 53 unfractionated heparin UFH 53 etanercept 53 Initiate Phase 53 lopinavir ritonavir 53 dexamethasone Decadron 53 sulodexide 53 RezularTM 53 VADT 53 Phase 2b clinical trials 53 NOXAFIL 53 confirmatory Phase 3 53 UKPDS 53 intravenously administered 53 Phase IIb trials 53 Health Initiative WHI 53 evaluable subjects 53 IIa clinical 53 Trandolapril 53 prespecified 53 μg kg 53 RECORD1 53 EFAPROXYN 53 FOLFIRI 53 Ovarian PLCO Cancer 53 tarenflurbil 52 genotype 1a 52 BOLDER 52 galiximab 52 albinterferon alfa 2b 52 LibiGel Phase III 52 By JENNIFER LEARN 52 Phase 1b clinical trials 52 bevacizumab 52 afatinib 52 Group B CALGB 52 interferon beta 1b 52 Rosuvastatin 52 eplerenone 52 subcutaneous methylnaltrexone 52 intravenous dose 52 mg d 52 lanthanum carbonate 52 designated HVTN 52 EQUATE OB 52 sitagliptin 52 REMINYL ® 52 Metabolic Efficiency 52 Multicenter Randomized Double 52 cisplatin vinorelbine 52 number NCT# ClinicalTrials.gov 52 Teriflunomide 52 Pemetrexed 52 tolvaptan 52 events AEs 52 SEROQUEL 52 Sapacitabine 52 docetaxel 52 Oral Fingolimod 52 pharmacodynamic PD 52 ELONVA 52 SCIg 52 Sequenced Treatment Alternatives 52 EXPAREL TM 52 dapagliflozin plus 52 hyperlipidemic 52 pegylated interferon 52 oral prodrug 52 allopurinol 52 evaluating carfilzomib 52 meta analyzes 52 IMPROVE IT 52 HYVET 52 sirolimus eluting stent 52 mcg doses 52 oral FTY# 52 randomized discontinuation trial 52 edoxaban 52 abacavir lamivudine 52 Phase 1b dose escalation 52 pharmacokinetic profiles 52 Imprime PGG 52 investigational compound 52 MADIT II 52 Peginterferon 52 VFEND 52 VA# [002] 52 solifenacin 52 valsartan 52 cinacalcet 52 TMC# [002] 52 DPNP 52 DLTs 52 #mg QD [001] 52 XIENCE V Stent System 52 CONQUER OB 52 CRLX# 52 Phase IIA 52 median PFS 52 telcagepant 52 direct thrombin inhibitor 52 DP b# 52 azacitidine 52 ALLHAT 52 IFN α 52 bicifadine 52 landmark ATHENA study 52 Androxal TM 52 BAY #-# 52 evaluating Xcytrin 52 Ozarelix 52 alicaforsen enema 52 polymerase inhibitor 52 RADIANT 52 retinal thickness 52 3TC lamivudine Epivir 52 eosinophilic asthma 52 CRVO 52 patients undergoing percutaneous 52 ibandronate 52 BMS # 52 BENICAR HCT 52 Tarceva TM 52 febuxostat 52 recurrent GBM 52 MAGE A3 ASCI 52 HGS# 52 TAXUS V 52 lomitapide 52 Linagliptin 52 CALGB # [001] 52 sorafenib Nexavar ® 52 Zocor simvastatin 52 Diabetic Macular Edema 52 paclitaxel eluting stents 52 statistically significant efficacy 52 NICE SUGAR 52 cell lymphoma CTCL 52 Navelbine 52 Peg IFN 52 Endovascular Valve Edge 52 ENGAGE AF TIMI 52 Prospective Randomized Trial 52 OPT CHF 52 Left Ventricular Dysfunction 52 ADMIRE HF 52 TMC# [001] 52 Prostate AdenoCarcinoma Treatment 52 IIa clinical trial 52 everolimus eluting stent 52 Study Evaluating 52 ORAL Sync 52 estramustine 52 Atrasentan 52 Intervention Trial 52 velafermin 52 LUMINATE 52 IDX# 52 octreotide LAR 52 NEVO RES 52 Dabigatran etexilate 52 TAXUS VI 52 deferiprone 52 mixed dyslipidemia 52 Naive Patients 52 EOquin TM 52 rt PA 52 elotuzumab 52 anti arrhythmic drug 52 tanespimycin 52 Blinatumomab 52 8mg/kg 52 GSK# [001] 52 ofatumumab 52 virus HCV protease inhibitor 52 PREZISTA ritonavir 52 pharmacokinetic pharmacodynamic 52 CHOP chemotherapy 52 atazanavir ritonavir 52 darunavir r 52 ONGLYZA 52 Thrombolysis 52 trastuzumab Herceptin R 52 relapsed APL 52 Acute Ischemic Stroke 52 protease inhibitor PI 52 TEMSO 52 subcutaneous SC 52 Pegasys plus Copegus 52 mycophenolate mofetil 52 ragweed allergic 52 fistulizing Crohn disease 52 KRAS mutations occur 52 ROZEREM TM 52 ARCOXIA 52 dose limiting toxicities 52 retaspimycin 52 pitavastatin 52 PROMACTA 52 assessing T DM1 52 IIa trial 52 PPAR gamma agonist 52 telmisartan 52 rilpivirine 52 ACCOMPLISH 52 eprotirome 52 ACUITY trial 52 Dasatinib 52 Perforomist Inhalation Solution 52 KRN# 52 abatacept 52 NEVO 52 ARDIS 52 Phase 2b dose 52 EMPHASIS HF trial 52 TG# [003] 52 migraine prophylaxis 52 CERVARIX 52 Phase III Clinical Trials 52 Cloretazine 52 VITAL Trial 52 mcg QD 52 olaparib 52 ritonavir boosted atazanavir 52 metastatic hormone refractory 52 ruboxistaurin 52 longitudinal study 52 International Verapamil SR 52 ziprasidone Geodon 52 idraparinux 52 RESOLUTE 52 RE MODEL 52 tipranavir r 52 subcutaneous formulation 52 somatostatin analog 52 daily subcutaneous injections 51 rosuvastatin Crestor 51 PRIMO CABG2 51 ovariectomized 51 Cimzia ® certolizumab pegol 51 timepoint 51 sorafenib tablets 51 salmeterol fluticasone 51 oral diclofenac 51 nulliparous women 51 mapatumumab 51 Phase 51 Doxil ® 51 QLT# 51 RIBBON 51 Taxotere R 51 paclitaxel carboplatin 51 oxycodone CR 51 metformin sulfonylurea 51 receptor tyrosine kinase inhibitor 51 resected pancreatic cancer 51 FASLODEX 51 tenofovir Viread 51 trial evaluating PRX# 51 Torisel 51 FREEDOMS 51 virologic response 51 orally administered 51 Allovectin 7 ® 51 CURRENT OASIS 7 51 antiviral efficacy 51 Carfilzomib 51 donepezil 51 Degarelix 51 oral iron chelator 51 PEG INTRON R 51 NATRECOR R 51 azilsartan medoxomil 51 mRCC 51 normotensive 51 relapsing remitting MS RRMS 51 comparing alemtuzumab 51 abacavir Ziagen 51 Platelet Inhibition 51 acute ischemic stroke 51 degarelix 51 Diabetic Macular Edema DME 51 induced macular edema 51 peginterferon alpha 2a 51 varespladib 51 Protelos 51 mGluR5 negative 51 evaluating nimotuzumab 51 stage IIIb IV 51 Dapagliflozin 51 pegaptanib 51 NP2 Enkephalin 51 STEALTH C 51 GW# [003] 51 Aflibercept 51 BRAF inhibitor 51 plus dexamethasone 51 humanized interleukin 6 51 FOSRENOL R 51 doxorubicin docetaxel 51 antiretroviral naïve 51 Cooperative Oncology 51 angiotensin receptor blocker ARB 51 efficacy tolerability 51 HBeAg positive 51 Group RTOG 51 ZACTIMA 51 subcutaneous injections 51 diarrhea predominant irritable 51 peg IFN 51 PROPEL 51 Zenvia ™ 51 Azedra 51 CEQ# 51 liposomal formulation 51 olopatadine 51 temozolomide 51 RELOVAIR ™ 51 eptifibatide 51 LY# [003] 51 fallopian tube cancers 51 XL# SAR#